Considering the portrayed significance of the vWF-GPIb axis in preclinical ischemic-reperfusion injury models, caplacizumabs platelet-protective effect in thrombotic thrombocytopenic purpura (TTP) (197) raises hope that this novel vWF-inhibitor might be protective in patients with ischemic stroke as well. This evidence concerns the gene VWF and ischemic stroke.